According to related industries, Ultomiris (Ravulizumab), a treatment drug for paroxysmal nocturnal hemoglobinuria (PNH) supplied by Alexion to the domestic market, recently passed the D.C. of Seoul National University Hospital.

It will be quickly prescribed after obtaining approval from the MFDS in May last year and being listed on the insurance benefit list on April 7.

Solaris (30ml), at ₩5,132,364, so if three vials are administered bi-weekly per patient, ₩400 million is needed per year alone.

Ultomiris was listed at ₩5,598,942 per bottle, and Ultomiris can be administered once every eight weeks from two weeks after initial dose administration, which i